Core Viewpoint - The article analyzes the investment capabilities of Zhang Jintao, the fund manager of Huabao Medical Biology A, highlighting his strategic focus on the pharmaceutical industry's cyclical nature and the potential for significant returns in the innovative drug sector [3][4][32]. Fund Manager Information - Zhang Jintao has extensive experience in securities research and investment management, having worked with various financial institutions before joining Huabao Fund Management in April 2021 [6][30]. - Since taking over Huabao Medical Biology A on May 7, 2021, the fund has achieved a total scale of 629 million yuan, outperforming nearly 80% of its peers in the pharmaceutical theme fund category [7][30]. Investment Strategy - Zhang's investment framework is centered around the "industry cycle," integrating policy, industry, and valuation dimensions to capture the cyclical movements of the global pharmaceutical industry [3][32]. - The current phase of the Chinese innovative drug industry is viewed as a harvest period following a decade of R&D investment, with a shift in driving logic from domestic medical insurance expansion to global market share competition [3][4][16]. Portfolio Construction - The fund maintains a high allocation to innovative drugs, reflecting Zhang's belief that the industry is at the beginning of a harvest phase [3][20]. - The strategy involves focusing on companies expected to launch significant products or experience rapid growth in the next 2-3 years, aiming for alpha returns within the innovative drug sector [15][20]. Dynamic Optimization - Zhang emphasizes the importance of dynamic portfolio management, adjusting stock positions based on market conditions and individual company performance [26][27]. - The fund's turnover rate is primarily driven by optimizing non-core holdings, while the top ten positions remain stable unless there are significant changes in fundamentals [26][27]. Performance Metrics - Since Zhang's tenure, Huabao Medical Biology A has recorded a cumulative excess return of 40.27%, significantly outperforming the overall pharmaceutical index [8][10]. - The fund's annualized return and volatility metrics indicate a strong performance relative to peers, although it exhibits slightly weaker defensive characteristics [11][12].

Group 1: Report Summary - The report analyzes the investment value of Zhang Jintao, a fund manager at Huabao Fund, with a focus on his performance in managing Huabao Pharmaceutical Biology A [1][4]. - Zhang Jintao has developed an investment methodology that combines industry cycle analysis with a multi - dimensional framework, showing strong adaptability in the current era of global opportunities for Chinese innovative drugs [5][20]. - Since Zhang Jintao took office, Huabao Pharmaceutical Biology A has achieved above - average returns among pharmaceutical theme funds, outperforming nearly 80% of its peers, with relatively strong offensive capabilities [4][16]. Group 2: Fund Manager Information 2.1 Fund Manager Introduction - Zhang Jintao has worked in multiple financial institutions, including Huatai United Securities, ABC Fortune Fund, etc. He joined Huabao Fund in April 2021 and has served as the fund manager of multiple funds since May 2021 [4][10]. 2.2 Management Product Introduction 2.2.1 Representative Product - Zhang Jintao has managed Huabao Pharmaceutical Biology A (240020.OF) since May 7, 2021, with a total scale of 629 million yuan as of September 30, 2025 [11]. 2.2.2 Representative Product Net Value Performance - After Zhang Jintao took office, excluding the 3 - month construction period, Huabao Pharmaceutical Biology A significantly outperformed the All - Index Pharmaceutical Index, achieving a cumulative positive excess return of 40.27% [12]. - In terms of performance among peers, it ranks in the upper - middle position, but its risk - control indicators such as volatility are relatively weak. Overall, it still has good cost - effectiveness [16]. Group 3: Fund Manager Investment Ability Analysis 3.1 Investment Scope - Guided by Industry Cycle and Anchored by Market Value Space - Zhang Jintao's investment system is based on a deep understanding of the "five - year cycle" of the pharmaceutical industry. He believes that the Chinese innovative drug industry has entered the stage of results realization after a long - term R & D investment period [21]. - He has constructed a "policy - industry - valuation" three - dimensional decision - making framework. The policy dimension focuses on understanding policy intentions; the industry dimension focuses on verifying industry and company fundamentals; the valuation dimension calculates the long - term target market value to evaluate risk - return ratios [21][22]. 3.2 Holding Characteristics - Portfolio Construction Highlights Industry Thinking - Zhang Jintao highly concentrates on the innovative drug sector, aiming to obtain alpha returns within the innovative drug industry by focusing on companies with upcoming blockbuster products or in the rapid - volume - growth stage [20][30]. - He also strategically allocates about 8% of the portfolio to the CXO sector as a supplement and risk - hedge. His average holding period is about 1 - 2 years, and he emphasizes dynamic adjustment [30]. 3.3 Operational Characteristics - Keeping Pace with the Times and Dynamically Optimizing - Zhang Jintao maintains a high stock position, believing that it is difficult to obtain excess returns through position timing in the pharmaceutical industry. Instead, he focuses on stock selection [35]. - The portfolio's turnover mainly comes from the optimization of non - core positions. The top ten heavy - holding stocks remain relatively stable, while the tail positions are adjusted more frequently to track new industry trends [35]. - The holding concentration is adjusted dynamically according to the industry stage, with a relatively dispersed strategy in the early stage and a gradually increasing concentration as the industry trend becomes clearer [35]. Group 4: Conclusion - Zhang Jintao's investment methodology combines industry - level strategic judgment with individual - stock tactical selection, showing strong adaptability and viability in the context of the global opportunities for Chinese innovative drugs [45][46]. - Huabao Pharmaceutical Biology A, under his management, has achieved good performance among pharmaceutical theme funds, with relatively strong offensive capabilities but slightly weaker defensiveness [44].

↑点击上面图片 加雪球核心交流群 ↑ 2 ） 学习成本较高 ： 需要熟悉所有不同疾病领域 ， 例如肿瘤 、 自免等大类疾病下面还有若干细分 ， 均需要深入学习 3 ） 行业变化快 ： 可能一个月不跟踪就会有新的变化 ， 包括相关药物的进展发生变化 ， 新的数据披露等等 二 、 在不那么深入研究的情况下 ， 要如何投资创新药 ， 我觉得首先需要搞清楚创新药投资的阶段 ， 那么创新药投资不同阶段如何划分呢 ？ 关于这个问题 ， 首先需要明确一个观点 ， 就是在国内医药市场医保长期控费的大背景下 ， 创新药板块大的增量空间主要还是来自于出海 ， 大 多数创新药公司市值的增长主要由出海驱动 。 而当前出海最主流的形式就是海外授权BD ， 而以海外授权BD作为核心关注点 ， 我认为创新药投 资阶段主要可以划分成 ： 风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 野生创新药研究猿 来源：雪球 从事创新药行业研究以来 ， 接触的客户形形色色 ， 但是绝大部分人都没有创新药的专业背景 ， 而且很多人也没有精力再去深入研究这个领域 ， 因此我被问得最多便是 ： 创新药作为高风险的 ...

东吴证券表示，展望2026年，创新药仍将是投资主线。主要原因是创新药国际地位有赶超之势、BD出 海井喷式增长、市值空间大及业绩进入扭亏盈利阶段等，新一代ADC+2.0 IO及小核酸等将是创新药重 点方向。 （文章来源：每日经济新闻） 今日，创新药强势反弹，科创创新药ETF（589720）涨超3%，资金也在积极布局，近10日净流入额超 2.7亿元。 科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创板创 新药指数，以高成长biotech为主，产品20%涨跌幅限制使其更贴合板块波动。 ...

Group 1 - The gold and innovative drug sectors continue to rise, with the gold ETF Huaxia increasing by 1.41% and the more elastic gold stock ETF rising by 3.12%, while the Hang Seng Pharmaceutical ETF gained 3.36%, marking two consecutive days of gains [1] - Spot gold rebounded to $4,196.54 per ounce, aiming for the $4,200 mark, following the signing of a federal government temporary funding bill by President Trump, which ended a 43-day government shutdown, improving dollar liquidity and boosting both risk and safe-haven assets [2] - BeiGene's stock surged over 6%, reaching a four-year high, with Q3 revenue of 10.077 billion yuan, a year-on-year increase of 41.1%, and both Q3 and year-to-date net profits turning positive [2] Group 2 - The gold ETF Huaxia (518850) tracks the SGE Gold 9999 Index with a total fee rate of 0.2%, the lowest in its category, while the gold stock ETF (159562) tracks SSH gold stocks, primarily consisting of gold and copper, with a similar fee rate [2] - The Hang Seng Pharmaceutical ETF (159892) represents the global pharmaceutical industry chain with a latest scale of 6.15 billion yuan, featuring top-weighted stocks including BeiGene, WuXi Biologics, and others [3] - Recent inflows into gold ETFs have been significant, with a net inflow of 1.26 billion yuan in a single day, and the Huaxia gold ETF attracting net inflows for 10 consecutive days, totaling 2.015 billion yuan over the past 20 days [2]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a strong performance, driven by the rise of the National Index for Hong Kong Innovative Drugs, with leading stocks such as BeiGene, InnoCare Pharma, and 3SBio showing significant gains [1] Group 1: Market Performance - The Hong Kong Innovative Drug ETF (159567) opened higher and rose over 3% by 9:50 AM, with a trading volume exceeding 600 million yuan, indicating a slight increase compared to the previous day [1] - The strong performance of the index has positively influenced the trading activity of popular ETFs in the market [1] Group 2: Investment Outlook - CITIC Securities released a report forecasting the investment trends in the pharmaceutical sector through 2026, highlighting the concentration of innovation among Chinese pharmaceutical companies and supportive policies for innovative drugs and medical devices [1] - The healthcare industry is expected to gradually return to a market pricing system driven by clinical value and demand, leading to a stable and sustainable domestic pharmaceutical market environment [1] - Listed companies in the sector are anticipated to experience continuous and stable earnings growth, contributing to a positive growth outlook for the industry [1] Group 3: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the National Index for Hong Kong Innovative Drugs, aiming to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [1] - Investors can also access the Hong Kong Innovative Drug ETF through connecting funds, providing an opportunity to capitalize on the upward potential of the innovative drug sector [1]

"展望未来，创新药仍是值得关注的一个重要细分赛道，但是标的上需要精挑细选，估值方面也会趋于 理性。"丁天宇表示，"整个医药板块除了创新药及产业链外，其他赛道估值相对较低，随着基本面逐步 好转，医药板块有望涌现更多的投资机会。" 中证报中证网讯(记者王雪青)11月11日晚间，中金基金权益部基金经理丁天宇在"中证点金汇"直播间表 示，近期创新药板块回调，一方面是前期预期过高，一些临床早期项目被给予了全球数十亿美元的市场 估值，几个大BD(业务拓展，常指海外授权)拉高了市场对潜在BD项目的预期，且有几个50亿美元以上 的BD项目预期下半年可能落地；另一方面是三季度开始，创新药的催化事件变少，超预期数据发布较 少，预期中的大型BD项目也推迟或不及预期，进而导致板块回调。 ...

二级市场方面，本轮调整在时间和空间维度都较为充分。历史上，创新药指数的回调平均时长在30-40 天，幅度在20%附近。少数几次跌破阈值的行情都伴随极端事件比如加息、疫情透支这种罕见事件。而 在创新药产业趋势确定的背景下，本轮调整时长已近一个季度，指数跌幅已超过20%。此外，大型配置 型机构除在年底纷纷止盈外，也需要为明年布局。 获益于资金坚定逆行增仓，港股通创新药ETF（520880）份额与规模逆市增长。11月3日，基金规模首 次突破20亿元，自7月7日上市以来猛增392%！11月10日，基金份额升至37.84亿份，续创上市新高！ 立足当下，如何看待创新药本轮调整，操作层面又该何去何从？ 港股通创新药ETF（520880）基金经理丰晨成最新重申：创新药行情可能随时开启，当下或处于高胜率 区间。 创新药本轮调整可能仍在寻底。从创新药含量100%的港股通创新药ETF（520880）走势来看，11月以 来多次反抽，但行情尚缺持续性，单周内表现多涨跌互现。本周，周一（11月10日）反弹1.28%，周二 又回调0.54%。 创新药还能买吗？资金用脚投票。港股通创新药ETF（520880）资金动向与行情走势截然相反，9月 ...

文 | 海若镜 "投资就是投人"，这一在风险投资领域流传甚广的金句，似乎定义了一种信仰。 然而，在维梧资本（Vivo Capital）管理合伙人付山看来，这一常识在创新药投资中，需要重新审视。 他认为，生物医药领域，最硬核的通货是资产——那些有巨大成药潜力和商业价值的分子、技术和管 线。 "十年前，我们就曾在内部激烈讨论：新药投资到底是投人，还是资产？"付山回忆道，"最终我们下定 决心：投资产。" 横跨中美资本市场，让付山得以从全球坐标系审视创新药产业变迁。他表示，传统VC投资创新药企的 模式已显疲态，创新药研发急需新的组织方式，来降低试错成本。 维梧加速器是他们选择的新道路：在全球范围内筛选优质的新药资产，通过组建新公司（NewCo）模 式，将其引入中国。借助中国在过去20年间积累的"系统集成优势"——工程师红利、CXO平台能力、临 床试验资源等，以最快的效率、最低的成本试错，验证资产价值。 2025年3月，维梧资本公开市场策略完成募集7.4亿美元；当前在管资产管理规模超75亿美元。付山认 为，维梧资本最大的本质是"变"。 主动求变，让这家在资本市场跨越三十年的投资机构，收获了一系列成绩：2021年至今，有 ...

Core Insights - Merck has initiated 15 global Phase 3 clinical trials for the TROP-2 ADC drug sacituzumab tirumotecan, enrolling 15,000 patients, indicating strong confidence in this therapeutic area [1] - Blackstone's investment of $700 million in the drug's clinical development reflects a strategic partnership aimed at mitigating the high risks associated with innovative drug development [1][2] - The collaboration allows Merck to balance innovation risks while potentially reaping significant rewards if Blackstone meets sales targets [3] Financial Implications - Blackstone's return on investment hinges on achieving a global sales target of approximately $17.5 billion, assuming a 4% royalty fee, to cover its initial $700 million investment [2] - The sales performance of Gilead's TROP-2 ADC drug suggests that reaching such targets may take considerable time, as Gilead's drug generated $1.315 billion in 2024 and $1.013 billion in the first three quarters of 2025 [2] Strategic Collaboration Model - Blackstone's approach to partnering with Merck represents a shift in collaboration strategies within the pharmaceutical industry, focusing on individual pipeline projects rather than equity stakes or new company formations [6][8] - This model preserves operational autonomy for the drug company while enhancing funding efficiency, allowing for better control over research and development directions [7][8] - The collaboration reduces operational costs and avoids the complexities associated with establishing new entities, thereby accelerating the drug approval and commercialization processes [7][8]